JPRN-UMIN000044385
Recruiting
未知
A study on the safety and effectiveness of "a weight loss program by setting energy intake considering changes in basal metabolic rate" - A weight loss program by setting energy intake considering changes in basal metabolic rate
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine0 sites20 target enrollmentJune 1, 2021
ConditionsObesity
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Obesity
- Sponsor
- Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The exclusion criteria are as follows: 1\) Secondary obesity (symptomatic obesity) 2\) Patients who had a history of highly invasive surgery, severe trauma, severe infection disease, malignant tumor, or hyperthyroidism within six months 3\) Patients with severe impairment in cardiorespiratory, renal or liver function to whom exercise therapy is not applicable (includes patients estimated glomerular filtration rate \< 30 mL/min/1\.73 m2\) 4\) Patients with severe musculoskeletal impairment to whom exercise therapy is not applicable 5\) Patients who are pregnant, suspected of being pregnant, within 28 days of parturition, or breastfeeding 6\) Patients who are judged by their physicians to be unsuitable for participation in the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
study on overall improvement of Skin ParametersCTRI/2023/06/054242Transformative Learning Solutions Pvt Ltd75
Active, not recruiting
Not Applicable
A study to determine the safety and efficacy of a terbinafine topical formulation system in subjects with onychomycosis in laser treated toenails versus ciclopirox lacquer in intact toenailsDistal/lateral Subungual onychomycosis (DSO) caused by dermatophytesMedDRA version: 8.1Level: LLTClassification code 10030338Term: OnychomycosisEUCTR2006-005895-42-ISTLT Medical Ltd.235
Active, not recruiting
Phase 1
A Study to Evaluate the Safety and efficacy of the Antibody APX005M in Adult Patients with Metastatic Melanoma Who have not Received Prior Immunotherapynresectable or metastatic melanomaMedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-003864-30-ESApexigen, Inc.36
Active, not recruiting
Phase 1
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanomaon-small Cell Lung Cancer and Metastatic MelanomaMedDRA version: 20.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10027481 Term: Metastatic melanoma System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-003866-14-ESApexigen, Inc.174
Active, not recruiting
Phase 1
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanomaon-small Cell Lung Cancer and Metastatic MelanomaMedDRA version: 20.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-003866-14-FRApexigen, Inc.174